Patents by Inventor Phillip Tai

Phillip Tai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240082817
    Abstract: The invention concerns biocompatible polymer systems comprising at least one polymer with a plurality of pores, said polymer comprising either polyol or zwitterionic groups designed to adsorb endotoxins and other inflammatory mediator molecules.
    Type: Application
    Filed: November 6, 2023
    Publication date: March 14, 2024
    Inventors: Tamaz Guliashvili, Thomas Golobish, Maryann Gruda, Pamela O'Sullivan, Andrew Scheirer, Vincent Capponi, Phillip Chan, Wei-Tai Young
  • Patent number: 11926842
    Abstract: In some aspects, the disclosure provides recombinant AAV and nucleic acid constructs having novel inverted terminal repeats (ITRs), cap, and/or rep genes. In some aspects, the disclosure relates to gene transfer methods using rAAVs described herein.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: March 12, 2024
    Assignee: University of Massachusetts
    Inventors: Guangping Gao, Phillip Tai, Elisabet C. Mandon, Jianzhong Ai
  • Patent number: 11851657
    Abstract: The disclosure relates, in some aspects, to compositions and methods for treating corneal disease (e.g., corneal neovascularization. In some embodiments, the disclosure relates to rAAV-mediated delivery of an cornea-associated transgene to a subject. In some embodiments, the rAAV transduces the corneal tissue of a subject.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: December 26, 2023
    Assignee: University of Massachusetts
    Inventors: Guangping Gao, Yi Lu, Qiang Zheng, Xun Xu, Phillip D. Zamore, Phillip Tai
  • Publication number: 20230374545
    Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.
    Type: Application
    Filed: January 5, 2023
    Publication date: November 23, 2023
    Applicants: University of Massachusetts, Sichuan University
    Inventors: Guangping Gao, Guangchao Xu, Phillip Tai, Yuquan Wei, Li Luo
  • Publication number: 20230332180
    Abstract: The disclosure, in some aspects, relates to nucleic acids, compositions and kits useful for gene therapy with reduced immune response to transgene products.
    Type: Application
    Filed: April 10, 2023
    Publication date: October 19, 2023
    Applicant: University of Massachusetts
    Inventors: Guangping Gao, Phillip Tai, Manish Muhuri, Wei Zhan
  • Patent number: 11655483
    Abstract: The disclosure, in some aspects, relates to nucleic acids, compositions and kits useful for gene therapy with reduced immune response to transgene products.
    Type: Grant
    Filed: January 21, 2022
    Date of Patent: May 23, 2023
    Assignee: University of Massachusetts
    Inventors: Guangping Gao, Phillip Tai, Manish Muhuri, Wei Zhan
  • Publication number: 20230138766
    Abstract: Aspects of the disclosure relate to compositions and methods for delivering a transgene (e.g., a transgene encoding one or more gene products) to a target cell. The disclosure is based, in part, on adeno-associated virus (AAV) capsid protein variants characterized by tropisms for certain cell types (e.g., neurons, muscle cells, bone cells, heart cells, etc.). In some embodiments, recombinant A A Vs (rAAVs) comprising the capsid protein variants (e.g., AAVv66, SEQ ID NO: 1) are more efficiently packaged than rAAVs having certain wild-type AAV capsid proteins. Methods of delivering an rAAV comprising the AAV capsid protein variants are also described by the disclosure.
    Type: Application
    Filed: March 30, 2021
    Publication date: May 4, 2023
    Applicants: University of Massachusetts, Sichuan University
    Inventors: Guangping Gao, Guangchao Xu, Phillip Tai, Yuquan Wei, Li Luo
  • Publication number: 20230057380
    Abstract: Aspects of the disclosure relate to a recombinant adeno-virus encoding an anti-Vascular endothelial cell growth factor (VEGF) agent in a cell or subject (e.g., rAAV2.7m8-KH902). In some embodiments, compositions described herein are useful for treating subjects having diseases associated with angiogenesis or aberrant VEGF activity/signaling.
    Type: Application
    Filed: November 25, 2020
    Publication date: February 23, 2023
    Applicants: University of Massachusetts, Chengdu Kanghong Biotechnology Co. Ltd.
    Inventors: Guangping Gao, Phillip Tai, Claudio Punzo, Zunhong Ke
  • Publication number: 20230048017
    Abstract: Aspects of the disclosure relate to compositions and methods for expressing anti-Vascular endothelial cell growth factor (VEGF) agent in a cell or subject. In some embodiments, the disclosure provides rAAVs comprising a capsid protein (e.g., AAV2 variants, AAV2/3 hybrid variants, AAV8 variants, etc.), and a transgene encoding an anti-VEGF agent (e.g., KH902) and one or more regulatory sequences. In some embodiments, compositions described herein are useful for treating subjects having diseases associated with angiogenesis or aberrant VEGF activity/signaling.
    Type: Application
    Filed: March 3, 2022
    Publication date: February 16, 2023
    Applicant: University of Massachusetts
    Inventors: Guangping Gao, Phillip Tai, Claudio Punzo, Haijiang Lin
  • Patent number: 11578340
    Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: February 14, 2023
    Assignees: University of Massachusetts, Sichuan University
    Inventors: Guangping Gao, Guangchao Xu, Phillip Tai, Yuquan Wei, Li Luo
  • Publication number: 20220332792
    Abstract: Aspects of the disclosure relate to compositions and methods for expressing one or more anti-Vascular endothelial cell growth factor (VEGF) agents in a cell or subject. In some embodiments, the disclosure provides isolated nucleic acids and rAAVs comprising a transgene encoding an anti-VEGF agent (e.g., KH902) and one or more regulatory sequences. In some embodiments, compositions described herein are useful for treating subjects having diseases associated with angiogenesis or aberrant VEGF activity/signaling.
    Type: Application
    Filed: September 3, 2020
    Publication date: October 20, 2022
    Applicant: University of Massachusetts
    Inventors: Guangping Gao, Phillip Tai, Claudio Punzo
  • Publication number: 20220251602
    Abstract: In some aspects, the disclosure provides recombinant AAV and nucleic acid constructs having novel inverted terminal repeats (ITRs), cap, and/or rep genes. In some aspects, the disclosure relates to gene transfer methods using rAAVs described herein.
    Type: Application
    Filed: February 1, 2022
    Publication date: August 11, 2022
    Applicant: University of Massachusetts
    Inventors: Guangping Gao, Phillip Tai, Elisabet C. Mandon, Jianzhong Ai
  • Publication number: 20220235372
    Abstract: The disclosure, in some aspects, relates to nucleic acids, compositions and kits useful for gene therapy with reduced immune response to transgene products.
    Type: Application
    Filed: January 21, 2022
    Publication date: July 28, 2022
    Applicant: University of Massachusetts
    Inventors: Guangping Gao, Phillip Tai, Manish Muhuri, Wei Zhan
  • Publication number: 20210380981
    Abstract: The disclosure relates, in some aspects, to compositions and methods for treating corneal disease (e.g., corneal neovascularization. In some embodiments, the disclosure relates to rAAV-mediated delivery of an cornea-associated transgene to a subject. In some embodiments, the rAAV transduces the corneal tissue of a subject.
    Type: Application
    Filed: June 9, 2021
    Publication date: December 9, 2021
    Applicant: University of Massachusetts
    Inventors: Guangping Gao, Yi Lu, Qiang Zheng, Xun Xu, Phillip D. Zamore, Phillip Tai
  • Patent number: 11060088
    Abstract: The disclosure relates, in some aspects, to compositions and methods for treating corneal disease (e.g., corneal neovascularization. In some embodiments, the disclosure relates to rAAV-mediated delivery of an cornea-associated transgene to a subject. In some embodiments, the rAAV transduces the corneal tissue of a subject.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: July 13, 2021
    Assignee: University of Massachusetts
    Inventors: Guangping Gao, Yi Lu, Qiang Zheng, Xu Xun, Phillip D. Zamore, Phillip Tai
  • Publication number: 20200316221
    Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.
    Type: Application
    Filed: April 7, 2020
    Publication date: October 8, 2020
    Applicant: University of Massachusetts
    Inventors: Guangping Gao, Guangchao Xu, Phillip Tai, Yuquan Wei, Li Luo
  • Publication number: 20190300904
    Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.
    Type: Application
    Filed: October 13, 2017
    Publication date: October 3, 2019
    Applicant: University of Massachusetts
    Inventors: Guangping Gao, Guangchao Xu, Phillip Tai, Yuquan Wei, Li Luo
  • Publication number: 20190048343
    Abstract: The disclosure relates, in some aspects, to compositions and methods for treating corneal disease (e.g., corneal neovascularization. In some embodiments, the disclosure relates to rAAV-mediated delivery of an cornea-associated transgene to a subject. In some embodiments, the rAAV transduces the corneal tissue of a subject.
    Type: Application
    Filed: February 10, 2017
    Publication date: February 14, 2019
    Applicant: University of Massachusetts
    Inventors: Guangping Gao, YI Lu, Qiang Zheng, Xu Xun, Phillip D. Zamore, Phillip Tai